[Federal Register Volume 79, Number 148 (Friday, August 1, 2014)]
[Notices]
[Pages 44787-44792]
[FR Doc No: 2014-18110]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0007]

Animal Drug User Fee Rates and Payment Procedures for Fiscal Year
2015

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the rates
and payment procedures for fiscal year (FY) 2015 animal drug user fees.
The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by
the Animal Drug User Fee Amendments of 2013 (ADUFA III), authorizes FDA
to collect user fees for certain animal drug applications and
supplements, for certain animal drug products, for certain
establishments where such products are made, and for certain sponsors
of such animal drug applications and/or investigational animal drug
submissions. This document establishes the fee rates for FY 2015.

FOR FURTHER INFORMATION CONTACT: Visit FDA's Web site at http://www.fda.gov/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/default.htm
or contact Lisa Kable,

Center for Veterinary Medicine (HFV-10), Food and Drug Administration,
7529 Standish Pl., Rockville, MD 20855,<PHONE_NUMBER>. For general
questions, you may also email the Center for Veterinary Medicine (CVM)
at<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Background

    Section 740 of the FD&C Act (21 U.S.C. 379j-12) establishes four
different types of user fees: (1) Fees for certain types of animal drug
applications and supplements; (2) annual fees for certain animal drug
products; (3) annual fees for certain establishments where such
products are made; and (4) annual fees for certain sponsors of animal
drug applications and/or investigational animal drug submissions (21
U.S.C. 379j-12(a)). When certain conditions are met, FDA will waive or
reduce fees (21 U.S.C. 379j-12(d)).
    For FY 2014 through FY 2018, the FD&C Act establishes aggregate
yearly base revenue amounts for each fiscal year (21 U.S.C. 379j-
12(b)(1)). Base revenue amounts established for years after FY 2014 are
subject to adjustment for inflation and workload (21 U.S.C. 379j-
12(c)). Fees for applications, establishments, products, and sponsors
are to be established each year by FDA so that the percentages of the
total revenue that is derived from each type of user fee will be as
follows: Revenue from application fees shall be 20 percent of total fee
revenue; revenue from product fees shall be 27 percent of total fee
revenue; revenue from establishment fees shall be 26 percent of total
fee revenue; and revenue from sponsor fees shall be 27 percent of total
fee revenue (21 U.S.C. 379j-12(b)(2)).
    For FY 2015, the animal drug user fee rates are: $400,600 for an
animal drug application; $200,300 for a supplemental animal drug
application for which safety or effectiveness data are required and for
an animal drug application subject to the criteria set forth in section
512(d)(4) of the FD&C Act (21 U.S.C. 360b(d)(4)); $8,075 for an annual
product fee; $104,150 for an annual establishment fee; and $94,450 for
an annual sponsor fee. FDA will issue invoices for FY 2015 product,
establishment, and sponsor fees by December 31, 2014, and payment will
be due by January 31, 2015. The application fee rates are effective for
applications submitted on or after October 1, 2014, and will remain in
effect through September 30, 2015. Applications will not be accepted
for review until FDA has received full payment of application fees and
any other animal drug user fees owed under ADUFA.

II. Revenue Amount for FY 2015

A. Statutory Fee Revenue Amounts

    ADUFA III (Title I of Pub. L. 113-14) specifies that the aggregate
fee revenue amount for FY 2015 for all animal drug user fee categories
is $21,600,000. (21 U.S.C. 379j-12(b)(1)(B).)

B. Inflation Adjustment to Fee Revenue Amount

    The fee revenue amount established in ADUFA III for FY 2015 and
subsequent years are subject to an inflation adjustment (21 U.S.C.
379j-12(c)(2)).
    The component of the inflation adjustment for payroll costs shall
be 1 plus the average annual percent change in the cost of all
personnel compensation and benefits (PC&B) paid per full-time
equivalent position (FTE) at FDA for the first three of the four
preceding fiscal years, multiplied by the proportion of PC&B costs to
total FDA costs for the first three of the preceding four fiscal years
(see 21 U.S.C. 379j-12(c)(2)(B)). The data on total PC&B paid and
numbers of FTE paid, from which the average cost per FTE can be
derived, are published in FDA's Justification of Estimates for
Appropriations Committees.
    Table 1 summarizes that actual cost and FTE data for the specified
fiscal years, and provides the percent change from the previous fiscal
year and the average percent change over the first three of the four
fiscal years preceding FY 2015. The 3-year average is 1.8829 percent.

              Table 1--FDA Personnel Compensation and Benefits (PC&B) Each Year and Percent Change
----------------------------------------------------------------------------------------------------------------
                                                                                3-Year average
             Fiscal year                     2011               2012               2013            (percent)
----------------------------------------------------------------------------------------------------------------
Total PC&B..........................     $1,761,655,000     $1,824,703,000     $1,927,703,000
Total FTE...........................             13,331             13,382             13,974
PC&B per FTE........................           $132,147           $136,355           $137,949
Percent Change from Previous Year...            1.2954%            3.1843%             1.169%             1.8829
----------------------------------------------------------------------------------------------------------------

    The statute specifies that this 1.8829 percent should be multiplied
by the proportion of PC&B costs to total FDA costs. Table 2 shows the
amount of PC&B and the total amount obligated by FDA for the same three
fiscal years.

             Table 2--Personnel Compensation and Benefits (PC&B) as a Percent of Total Costs at FDA
----------------------------------------------------------------------------------------------------------------
           Fiscal year                   2011                2012                2013           3-Year average
----------------------------------------------------------------------------------------------------------------
Total PC&B......................      $1,761,655,000      $1,824,703,000      $1,927,703,000
Total Costs.....................      $3,333,407,000      $3,550,496,000      $4,151,343,000
PC&B Percent....................            52.8485%            51.3929%            46.4356%            50.2257%
----------------------------------------------------------------------------------------------------------------

    The payroll adjustment is 1.8829 percent multiplied by 50.2257
percent (or .9457 percent).
    The statute specifies that the portion of the inflation adjustment
for non-payroll costs for FY 2015 is the average annual percent change
that occurred in the Consumer Price Index (CPI) for urban consumers
(Washington-Baltimore, DC-MD-VA-WV; not seasonally adjusted; all items
less food and energy; annual index) for the first 3 of the preceding 4
years of available data multiplied by the proportion of all costs other
than PC&B costs to total FDA costs (see 21 U.S.C. 379j-12(c)(2)(C)).
Table 3 provides the summary data for the percent change in the
specified CPI for the Baltimore-Washington area. The data from the
Bureau of Labor Statistics is shown in Table 3.

     Table 3--Annual and 3-Year Average Percent Change in Baltimore-Washington Area CPI Less Food and Energy
----------------------------------------------------------------------------------------------------------------
              Year                       2011                2012                2013           3-Year average
----------------------------------------------------------------------------------------------------------------
Annual CPI......................             140.963             144.413             146.953
Annual Percent Change...........             2.2694%             2.4475%             1.7588%             2.1586%
----------------------------------------------------------------------------------------------------------------

    To calculate the inflation adjustment for non-pay costs, we
multiply the 2.1586 percent by the proportion of all costs other than
PC&B to total FDA costs. Since 50.2257 percent was obligated for PC&B
as shown in Table 2, 49.7743 percent is the portion of costs other than
PC&B (100%-50.2257& = 49.7743 percent). The non-payroll adjustment is
2.1586 percent times 49.7743 percent, or 1.0744 percent.
    To complete the inflation adjustment, we add the payroll component
(0.9457 percent) to the non-pay component (1.0744 percent), for a total
inflation adjustment of 2.0201 percent, and then add one, making
1.020201. We then multiply the base revenue amount for FY 2015
($21,600,000) by 1.020201, yielding an inflation adjusted amount of
$22,036,000 (rounded to the nearest thousand dollars).

C. Workload Adjustment to Inflation Adjusted Fee Revenue Amount

    A workload adjustment will be calculated to the inflation adjusted
fee revenue amount established in ADUFA III for FY 2015 and subsequent
fiscal years (21 U.S.C. 379j-12(c)(3)).
    FDA calculated the average number of each of the five types of
applications and submissions specified in the workload adjustment
provision (animal drug applications, supplemental animal drug
applications for which data with respect to safety or efficacy are
required, manufacturing supplemental animal drug applications,
investigational animal drug study submissions, and investigational
animal drug protocol submissions) received over the 5-year period that
ended on September 30, 2013 (the base years), and the average number of
each of these types of applications and submissions over the most
recent 5-year period that ended June 30, 2014.
    The results of these calculations are presented in the first two
columns of Table 4. Column 3 reflects the percent change in workload
over the two 5-year periods. Column 4 shows the weighting factor for
each type of application, reflecting how much of the total FDA animal
drug review workload was accounted for by each type of application or
submission in the table during the most recent 5 years. Column 5 is the
weighted percent change in each category of workload, and was derived
by multiplying the weighting factor in each line in column 4 by the
percent change from the base years in column 3. At the bottom right of
the table the sum of the values in column 5 is added, reflecting a
total change in workload of -0.47 percent for FY 2015. This is the
workload adjuster for FY 2015.

                                     Table 4--Workload Adjuster Calculation
                                      [Numbers may not add due to rounding]
----------------------------------------------------------------------------------------------------------------
                                                                                Column 5
                                                 Column 1 5-    Column 2     Column 3     Column 4     weighted
               Application type                   year avg.    latest 5-     percent     weighting     percent
                                                (base years)   year avg.      change       factor       change
----------------------------------------------------------------------------------------------------------------
New Animal Drug Applications (NADAs)..........          9.80         13.2           35       0.0214         0.74
Supplemental NADAs with Safety or Efficacy              9.6          11.4           19       0.0349         0.65
 Data.........................................
Manufacturing Supplements.....................        361.0         349.6           -3       0.1385        -0.44
Investigational Study Submissions.............        216.4         211.6           -2       0.6334        -1.41
Investigational Protocol Submissions..........        133.6         133.4            0       0.1718        -0.03
                                               -----------------------------------------------------------------
FY 2015 Workload Adjuster.....................  ............  ...........  ...........  ...........        -0.47
----------------------------------------------------------------------------------------------------------------

    ADUFA specifies that the workload adjuster may not result in fees
that are less than the fee revenue amount in the statute (21 U.S.C.
379j-12(c)(3)(C)). Because applying the FY 2015 workload adjuster would
result in fees less than the statutory amount, the workload adjustment
will not be applied in FY 2015. As a result, the statutory revenue
target amount for fees in FY 2015 remains at the inflation adjusted fee
revenue amount of $22,036,000.

D. FY 2015 Fee Revenue Amounts

    ADUFA III specifies that the revenue amount of $22,036,000 for FY
2015 is to be divided as follows: 20 percent, or a total of $4,407,000
(rounded to the nearest thousand dollars), is to come from application
fees; 27 percent, or a total of $5,950,000 (rounded to the nearest
thousand dollars), is to come from product fees; 26 percent, or a total
of $5,729,000 (rounded to the nearest thousand dollars), is to come
from establishment fees; and 27 percent, or a total of $5,950,000
(rounded to the nearest thousand dollars), is to come from sponsor fees
(21 U.S.C. 379j-12(b)).

III. Application Fee Calculations for FY 2015

    The terms ``animal drug application'' and ``supplemental animal
drug application'' are defined in section 739 of the FD&C Act (21
U.S.C. 379j-11(1) and (2)).

A. Application Fee Revenues and Numbers of Fee-Paying Applications

    The application fee must be paid for any animal drug application or
supplemental animal drug application that is subject to fees under
ADUFA and that is submitted on or after September 1, 2003. The
application fees are to be set so that they will generate $4,407,000 in
fee revenue for FY 2015. This is the amount derived in section II.D.
The fee for a supplemental animal drug application, for which safety or
effectiveness data are required, and for an animal drug application
subject to criteria set forth in section 512(d)(4) of the FD&C Act is
to be set at 50 percent of the animal drug application fee (21 U.S.C.
379j-12(a)(1)(A)(ii)).

    To set animal drug application fees and supplemental animal drug
application fees to realize $4,407,000 FDA must first make some
assumptions about the number of fee-paying applications and supplements
the Agency will receive in FY 2015.
    The Agency knows the number of applications that have been
submitted in previous years. That number fluctuates significantly from
year to year. In estimating the fee revenue to be generated by animal
drug application fees in FY 2015, FDA is assuming that the number of
applications that will pay fees in FY 2015 will equal the average
number of submissions over the five most recent completed years (FY
2009-FY 2013). This may not fully account for possible year-to-year
fluctuations in numbers of fee-paying applications, but FDA believes
that this is a reasonable approach after 10 years of experience with
this program.
    Over the five most recent completed years, the average number of
animal drug applications that would have been subject to the full fee
was 6.2. Over this same period, the average number of supplemental
applications and applications subject to the criteria set forth in
section 512(d)(4) of the FD&C Act that would have been subject to half
of the full fee was 9.6.

B. Fee Rates for FY 2015

    FDA must set the fee rates for FY 2015 so that the estimated 6.2
applications that pay the full fee and the estimated 9.6 supplemental
applications and applications subject to the criteria set forth in
section 512(d)(4) of the FD&C Act that pay half of the full fee will
generate a total of $4,407,000. To generate this amount, the fee for an
animal drug application, rounded to the nearest $100, will have to be
$400,600, and the fee for a supplemental animal drug application for
which safety or effectiveness data are required and for applications
subject to the criteria set forth in section 512(d)(4) of the FD&C Act
will have to be $200,300.

IV. Product Fee Calculations for FY 2015

A. Product Fee Revenues and Numbers of Fee-Paying Products

    The animal drug product fee (also referred to as the product fee)
must be paid annually by the person named as the applicant in a new
animal drug application or supplemental new animal drug application for
an animal drug product submitted for listing under section 510 of the
FD&C Act (21 U.S.C. 360), and who had an animal drug application or
supplemental animal drug application pending at FDA after September 1,
2003. (See 21 U.S.C. 379j-12(a)(2).) The term ``animal drug product''
means each specific strength or potency of a particular active
ingredient or ingredients in final dosage form marketed by a particular
manufacturer or distributor, which is uniquely identified by the
labeler code and product code portions of the national drug code, and
for which an animal drug application or a supplemental animal drug
application has been approved (21 U.S.C. 379j-11(3)). The product fees
are to be set so that they will generate $5,950,000 in fee revenue for
FY 2015. This is the amount derived in section II.D.
    To set animal drug product fees to realize $5,950,000, FDA must
make some assumptions about the number of products for which these fees
will be paid in FY 2015. FDA developed data on all animal drug products
that have been submitted for listing under section 510 of the FD&C Act
and matched this to the list of all persons who had an animal drug
application or supplement pending after September 1, 2003. As of June
2014, FDA estimates that there are a total of 768 products submitted
for listing by persons who had an animal drug application or
supplemental animal drug application pending after September 1, 2003.
Based on this, FDA estimates that a total of 768 products will be
subject to this fee in FY 2015.
    In estimating the fee revenue to be generated by animal drug
product fees in FY 2015, FDA is assuming that 4 percent of the products
invoiced, or 31, will not pay fees in FY 2015 due to fee waivers and
reductions. FDA has reduced the estimate of the percentage of products
that will not pay fees from 6 percent to 4 percent this year, based on
historical data over the past 5 years. Based on experience with other
user fee programs and the first 10 years of ADUFA, FDA believes that
this is a reasonable basis for estimating the number of fee-paying
products in FY 2015.
    Accordingly, the Agency estimates that a total of 737 (768 minus
31) products will be subject to product fees in FY 2015.

B. Product Fee Rates for FY 2015

    FDA must set the fee rates for FY 2015 so that the estimated 737
products that pay fees will generate a total of $5,950,000. To generate
this amount will require the fee for an animal drug product, rounded to
the nearest $5, to be $8,075.

V. Establishment Fee Calculations for FY 2015

A. Establishment Fee Revenues and Numbers of Fee-Paying Establishments

    The animal drug establishment fee (also referred to as the
establishment fee) must be paid annually by the person who: (1) Owns or
operates, directly or through an affiliate, an animal drug
establishment; (2) is named as the applicant in an animal drug
application or supplemental animal drug application for an animal drug
product submitted for listing under section 510 of the FD&C Act; (3)
had an animal drug application or supplemental animal drug application
pending at FDA after September 1, 2003; and (4) whose establishment
engaged in the manufacture of the animal drug product during the fiscal
year. (See 21 U.S.C. 379j-12(a)(3).) An establishment subject to animal
drug establishment fees is assessed only one such fee per fiscal year.
(See 21 U.S.C. 379j-12(a)(3).) The term ``animal drug establishment''
is defined in 21 U.S.C. 379j-11(4). The establishment fees are to be
set so that they will generate $5,729,000 in fee revenue for FY 2015.
This is the amount derived in section II.D.
    To set animal drug establishment fees to realize $5,729,000, FDA
must make some assumptions about the number of establishments for which
these fees will be paid in FY 2015. FDA developed data on all animal
drug establishments and matched this to the list of all persons who had
an animal drug application or supplement pending after September 1,
2003. As of June 2014, FDA estimates that there are a total of 62
establishments owned or operated by persons who had an animal drug
application or supplemental animal drug application pending after
September 1, 2003. Based on this, FDA believes that 62 establishments
will be subject to this fee in FY 2015.
    In estimating the fee revenue to be generated by animal drug
establishment fees in FY 2015, FDA is assuming that 12 percent of the
establishments invoiced, or 7, will not pay fees in FY 2015 due to fee
waivers and reductions. FDA has kept this estimate at 12 percent this
year, based on historical data over the past 5 years. Based on
experience with the first 10 years of ADUFA, FDA believes that this is
a reasonable basis for estimating the number of fee-paying
establishments in FY 2015.
    Accordingly, the Agency estimates that a total of 55 establishments
(62 minus 7) will be subject to establishment fees in FY 2015.

B. Establishment Fee Rates for FY 2015

    FDA must set the fee rates for FY 2015 so that the estimated 55
establishments that pay fees will generate a total of $5,729,000. To
generate this amount will require the fee for an animal drug
establishment, rounded to the nearest $50, to be $104,150.

VI. Sponsor Fee Calculations for FY 2015

A. Sponsor Fee Revenues and Numbers of Fee-Paying Sponsors

    The animal drug sponsor fee (also referred to as the sponsor fee)
must be paid annually by each person who: (1) Is named as the applicant
in an animal drug application, except for an approved application for
which all subject products have been removed from listing under section
510 of the FD&C Act, or has submitted an investigational animal drug
submission that has not been terminated or otherwise rendered inactive
and (2) had an animal drug application, supplemental animal drug
application, or investigational animal drug submission pending at FDA
after September 1, 2003. (See 21 U.S.C. 379j-11(6) and 379j-12(a)(4).)
An animal drug sponsor is subject to only one such fee each fiscal
year. (See 21 U.S.C. 379j-12(a)(4).) The sponsor fees are to be set so
that they will generate $5,950,000 in fee revenue for FY 2015. This is
the amount derived in section II.D.
    To set animal drug sponsor fees to realize $5,950,000, FDA must
make some assumptions about the number of sponsors who will pay these
fees in FY 2015. Based on the number of firms that would have met this
definition in each of the past 10 years, FDA estimates that a total of
179 sponsors will meet this definition in FY 2015.
    Careful review indicates that 33 percent of these sponsors will
qualify for minor use/minor species waiver or reduction (21 U.S.C.
379j-12(d)(1)(D)). Based on the Agency's experience to date with
sponsor fees, FDA's current best estimate is that an additional 32
percent will qualify for other waivers or reductions, for a total of 65
percent of the sponsors invoiced, or 116, who will not pay fees in FY
2015 due to fee waivers and reductions. FDA has kept this estimate at
65 percent this year, based on historical data over the past 5 years.
FDA believes that this is a reasonable basis for estimating the number
of fee-paying sponsors in FY 2015.
    Accordingly, the Agency estimates that a total of 63 sponsors (179
minus 116) will be subject to and pay sponsor fees in FY 2015.

B. Sponsor Fee Rates for FY 2015

    FDA must set the fee rates for FY 2015 so that the estimated 63
sponsors that pay fees will generate a total of $5,950,000. To generate
this amount will require the fee for an animal drug sponsor, rounded to
the nearest $50, to be $94,450.

VII. Fee Schedule for FY 2015

    The fee rates for FY 2015 are summarized in Table 5.

                       Table 5--FY 2015 Fee Rates
------------------------------------------------------------------------
                                                                Fee rate
                Animal drug user fee category                    for FY
                                                                  2015
------------------------------------------------------------------------
Animal Drug Application Fees:
    Animal Drug Application..................................   $400,600
    Supplemental Animal Drug Application for which Safety or     200,300
     Effectiveness Data are Required or Animal Drug
     Application Subject to the Criteria Set Forth in Section
     512(d)(4) of the FD&C Act...............................
Animal Drug Product Fee......................................      8,075
Animal Drug Establishment Fee \1\............................    104,150
Animal Drug Sponsor Fee \2\..................................     94,450
------------------------------------------------------------------------
\1\ An animal drug establishment is subject to only one such fee each
  fiscal year.
\2\ An animal drug sponsor is subject to only one such fee each fiscal
  year.

VIII. Procedures for Paying the FY 2015 Fees

A. Application Fees and Payment Instructions

    The appropriate application fee established in the new fee schedule
must be paid for an animal drug application or supplement subject to
fees under ADUFA that is submitted on or after October 1, 2014. Payment
must be made in U.S. currency by check, bank draft, or U.S. postal
money order payable to the order of the Food and Drug Administration,
by wire transfer, or electronically using http://www.pay.gov. (The
Pay.gov payment option is available to you after you submit a cover
sheet. Click the ``Pay Now'' button.) On your check, bank draft, or
U.S. postal money order, please write your application's unique Payment
Identification Number (PIN), beginning with the letters ``AD'', from
the upper right-hand corner of your completed Animal Drug User Fee
Cover Sheet. Also write the FDA post office box number (P.O. Box
979033) on the enclosed check, bank draft, or money order. Your payment
and a copy of the completed Animal Drug User Fee Cover Sheet can be
mailed to: Food and Drug Administration, P.O. Box 979033, St. Louis, MO
63197-9000.
    If payment is made by wire transfer, send payment to: U.S.
Department of Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045,
FDA Deposit Account Number: 75060099, U.S. Department of Treasury
routing/transit number: 021030004, SWIFT Number: FRNYUS33, Beneficiary:
FDA, 8455 Colesville Rd., Silver Spring, MD 20993-0002. You are
responsible for any administrative costs associated with the processing
of a wire transfer. Contact your bank or financial institution about
the fee and add it to your payment to ensure that your fee is fully
paid.
    If you prefer to send a check by a courier, the courier may deliver
the check and printed copy of the cover sheet to: U.S. Bank, Attn:
Government Lockbox 979033, 1005 Convention Plaza, St. Louis, MO 63101.
(Note: This address is for courier delivery only. If you have any
questions concerning courier delivery contact the U.S. Bank at 314-418-
4013. This telephone number is only for questions about courier
delivery.)
    The tax identification number of FDA is 53-0196965. (Note: In no
case should the payment for the fee be submitted to FDA with the
application.)
    It is helpful if the fee arrives at the bank at least a day or two
before the application arrives at FDA's CVM. FDA records the official
application receipt date as the later of the following: The date the
application was received by FDA's CVM, or the date U.S. Bank notifies
FDA that your payment in the full amount has been received, or when the
U.S. Treasury notifies FDA of receipt of an electronic or wire transfer
payment. U.S. Bank and the U.S. Treasury are required to notify FDA
within 1 working day, using the PIN described previously.

B. Application Cover Sheet Procedures

    Step One--Create a user account and password. Log on to the ADUFA
Web site at http://www.fda.gov/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/default.htm and, under Tools and Resources,
click ``The Animal Drug User Fee Cover Sheet'' and then click ``Create
ADUFA User Fee Cover Sheet.'' For security reasons, each firm
submitting an application will be assigned an organization
identification number, and each user will also be required to set up a
user account and password the first time you use this site. Online
instructions will walk you through this process.
    Step Two--Create an Animal Drug User Cover Sheet, transmit it to
FDA, and print a copy. After logging into your

account with your user name and password, complete the steps required
to create an Animal Drug User Fee Cover Sheet. One cover sheet is
needed for each animal drug application or supplement. Once you are
satisfied that the data on the cover sheet is accurate and you have
finalized the cover sheet, you will be able to transmit it
electronically to FDA and you will be able to print a copy of your
cover sheet showing your unique PIN.
    Step Three--Send the payment for your application as described in
section VIII.A.
    Step Four--Please submit your application and a copy of the
completed Animal Drug User Fee Cover Sheet to the following address:
Food and Drug Administration, Center for Veterinary Medicine, Document
Control Unit (HFV-199), 7500 Standish Pl., Rockville, MD 20855.

C. Product, Establishment, and Sponsor Fees

    By December 31, 2014, FDA will issue invoices and payment
instructions for product, establishment, and sponsor fees for FY 2015
using this fee schedule. Payment will be due by January 31, 2015. FDA
will issue invoices in November 2015 for any products, establishments,
and sponsors subject to fees for FY 2015 that qualify for fees after
the December 2014 billing.

    Dated: July 28, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-18110 Filed 7-31-14; 8:45 am]
BILLING CODE 4164-01-P